Clinical Trial Update: Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Creon 40,000 (pancrelipase) for pancreatic exocrine insufficiency due to chronic pancreatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Exocrine Insufficiency
• Pancreatitis

Drugs mentioned

• Creon 40,000 (pancrelipase)

Snippet

Sponsor: Abbott Products | Conditions: Pancreatic Insufficiency | Phase 3 | Status: COMPLETED